MedTrace Logo

Clinical Study of Lung-benefiting Moxibustion Reduce Exacerbations of Asthma

NCT06777472 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2025-01-15

No results posted yet for this study

Summary

For patients with poor asthma control, on the basis of treatment guided by GINA guidelines, lung-benefiting moxibustion treatment will be given, and it will be applied 10 days before "early onset", once every 10 days, and the follow-up was 45 weeks, 1 cycle per year, for 2 consecutive cycles (2 years). The annual number of flare-up of asthma patients will be used as the main outcome index to evaluate the clinical effect of lung-benefiting moxibustion on reducing exacerbations of asthma. By observing immunoglobulin, T cell subsets and other indicators, the advantage population and mechanism of moxibustion in treating patients with poor asthma control will be clarified.

Conditions

Interventions

OTHER

lung-benefiting moxibustion

A kind of external treatment，the treatment theory is to treat winter diseases in summer.

DRUG

The specific drug comes from "GINA (2024)"

Refer to "GINA (2024)".

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

    collaborator OTHER

  • Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator UNKNOWN

  • Cuiling Feng

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-09-30
Completion
2027-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06777472 on ClinicalTrials.gov